Saudi Arabia, public guidance
Saudi health ministry warns the public against using AI to diagnose themselves
AP - what was announcedThe Ministry of Health told the public that AI is no doctor and should not be asked to diagnose a condition, the Saudi news site Ajel reported on 17 November, citing the ministry's account on X. People can use it to understand their health, the post said, but should not give it test results and ask for a treatment plan. A second report the next day says the ministry accepts AI for explaining medical terms, giving general information about a disease or a test, and preparing questions for a consultation. It urges people to use the 937 call centre and the Sehhaty app.
Lateral - the other viewThe public may find that line hard to see, because the same report describes an AI tool inside the ministry's own Sehhaty app that takes symptoms and history by chat and writes a summary for the doctor before the consultation. Neither report says how that tool was tested, or how often its summary leaves out something a clinician would have asked.
Not disclosedWhat prompted the warning, the date of the ministry's post, and any figures on harm from self-diagnosis with AI.
Sources: Ajel (Arabic), Arabisk London (Arabic)
Kuwait, health ministry
Kuwait's health ministry describes a chatbot that explains patients' records and prescriptions
AP - what was announcedA Kuwaiti health ministry assistant undersecretary set out the ministry's digital tools on 11 November at an Arab League conference in Cairo, the Kuwait News Agency reported. One is an application he called a medical ChatGPT. It lets people explore their health records by text and voice, summarises and translates them and explains prescriptions, and he said it is meant for information and does not replace a doctor or pharmacist. He outlined the use of RapidAI to help diagnose stroke on non-contrast CT, and said AI that detects tissue abnormalities during colonoscopy is in advanced testing and clinical evaluation in Kuwait.
Lateral - the other viewA chatbot that explains a prescription can state a wrong dose as fluently as a right one, and the patient reading it has no way to tell. The report does not say which model is behind the application or whether patients can use it yet. Nothing is said about how the stroke and colonoscopy tools perform on scans and scopes done in Kuwait.
Not disclosedThe model behind the records chatbot, which of these tools are live, how many hospitals use RapidAI, and the size of the colonoscopy evaluation.
Source: Kuwait Times
Egypt, screening
Egypt's health minister and Huma discuss AI for the national screening programmes
AP - what was announcedEgypt's health minister met the founder and chief executive of Huma, a health technology company, to discuss using AI in the 100 Million Healthy Lives initiatives, state media reported on 16 November. The talks covered using the national databases those initiatives built to improve diagnostic accuracy, predict disease earlier and identify high-risk groups, with breast cancer screening and newborn care both mentioned. No agreement was reported. A week earlier, at Cairo ICT, the minister said AI is already part of early cancer detection and MRI analysis in Egypt, and one report of that speech names Roche as the partner in a national digital pathology network.
Lateral - the other viewNothing reported says who would hold the screening data once a company's models are trained on it, or whether any tool would be tested against Egyptian radiologists before it reads Egyptian mammograms.
Not disclosedWhich Huma products were discussed, any timeline, and the evidence behind the minister's statement that AI is already used in diagnosis.
Sources: Maspero (Arabic), El Balad on the Cairo ICT speech (Arabic), Cairo 24 (Arabic)
Abu Dhabi, oncology
Vivan Therapeutics approved to study AI treatment-ranking software in colorectal cancer in Abu Dhabi
AP - what was announcedVivan Therapeutics, a Hub71 startup, has received regulatory approval to begin a clinical registration study of its TuMatch software at Burjeel Cancer Institute, MENA Startup Digest reported on 13 November. TuMatch compares the genomic profile of a patient's tumour with the company's drug-response data and published evidence, then gives the oncologist a ranked list of treatment options. The prospective study will enrol at least 10 patients with colorectal cancer and will also collect health economics data for later talks on reimbursement. A larger multicentre study in pancreatic and other gastrointestinal cancers is planned for Europe and the Gulf.
Lateral - the other viewTen patients are enough to show the software can be run alongside a tumour board. Whether acting on its ranking changes response or survival needs a comparison group, and the report names neither a comparator nor a primary endpoint.
Not disclosedWhich regulator gave the approval, the trial registration, and who is funding the study.
Source: MENA Startup Digest